![Page 1: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/1.jpg)
Phase 2 Evaluation of Intravitreal Bevacizumab for DME
Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health and
Human Services.
![Page 2: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/2.jpg)
Study Objectives Assess the dose and dose interval related effects
of intravitreal bevacizumab on central retinal thickness and VA in subjects with DME
Assess the effects of intravitreal bevacizumab combined with focal photocoagulation in DME
Assess the safety of intravitreal bevacizumab in subjects with DME
![Page 3: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/3.jpg)
5 Treatment Groups Laser (0) Focal photocoagulation at baseline
Bev 1.25 (0,6) 1.25 mg intravitreal bevacizumab at baseline and at 6 wks
Bev 2.5 (0,6) 2.5 mg intravitreal bevacizumab at baseline and at 6 wks
Bev 1.25 (0) 1.25 mg intravitreal bevacizumab at baseline with sham injection at 6 wks
Bev 1.25 (0,6) + Laser (3)1.25 mg intravitreal bevacizumab at baseline, focal photocoagulation at 3 wks, and 1.25 mg intravitreal bevacizumab at 6 wks
![Page 4: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/4.jpg)
Efficacy Outcomes Central subfield thickness on OCT
![Page 5: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/5.jpg)
Electronic-ETDRS Visual Acuity (EVA)Efficacy Outcomes
![Page 6: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/6.jpg)
Study Phases Weeks 0-12: no other treatment was
to be given for DME in the study eye (study visits every 3 weeks)
Weeks 13-24: treatment depended on response to treatment given during the first 12 wks (study visits every 6 weeks)
After 24 weeks: follow-up for safety (study visits at 41 and at 70 weeks)
![Page 7: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/7.jpg)
Study Results Enrollment completed in 2 months
• 121 eyes of 121 subjects randomized• 109 eyes included in efficacy analyses
o Exclusions: 5 baseline CSF <275 um 1 nongradable baseline OCT 1 hx of laser 3 mos prior to randomization 2 CNV with diabetic retinopathy 2 no follow-up 1 endophthalmitis
• 19-24 subjects in each group
![Page 8: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/8.jpg)
Baseline CharacteristicsMedian age: 65 yrsWomen: 39%Caucasian: 76%Diabetes type: 1 – 7%, 2 – 93%Median duration of diabetes: 17 yrsNo prior DME treatment: 31%
![Page 9: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/9.jpg)
Baseline CharacteristicsVisual Acuity
Median (quartiles) letter score: 64 (71,56)
approx. Snellen equivalent 20/50 (20/40,20/80)
Central Subfield ThicknessMedian (quartiles) microns : 411 (334, 505)
![Page 10: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/10.jpg)
1. Does 1.25 mg bevacizumab have a positive effect on DME?
Compare Laser (0) vs. Bevacizumab 1.25 mg (0,6) at 3, 6, 9, and 12 weeks
![Page 11: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/11.jpg)
OCT Central Subfield ThicknessMedian Change (microns) from Baseline
Laser (0) N=19
Bev 1.25 (0,6)N=22
P value
3w +21 -35 .009
6w -40 -35 .22
9w -53 -74 .14
12w -40 -56 .32
![Page 12: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/12.jpg)
OCT Central Subfield Thickness <250 microns or >50% Decrease in Thickening
Laser (0)N=19
Bev 1.25 (0,6)N=22
3w 11% 37%
6w 17% 30%
9w 19% 38%
12w 21% 33%
![Page 13: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/13.jpg)
Visual Acuity Letter Score Median Change from Baseline
Laser (0)N=19
Bev 1.25 (0,6)N=22
P value
3w -2 +5 .06
6w +1 +5 .09
9w +3 +7 .07
12w -1 +5 .01
![Page 14: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/14.jpg)
Visual Acuity Letter ScoreIncrease > 10 from Baseline
Laser (0)N=19
Bev 1.25 (0,6)N=22
3w 6% 19%
6w 11% 32%
9w 18% 29%
12w 16% 33%
![Page 15: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/15.jpg)
2. Does 2.5 mg bevacizumab have a positive effect on DME?
Compare Laser (0) vs. Bevacizumab 2.5 mg (0,6) at 3, 6, 9, and 12 weeks
![Page 16: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/16.jpg)
OCT Central Subfield ThicknessMedian Change (microns) from Baseline
Laser (0)N=19
Bev 2.5 (0,6)N=24
P value
3w +21 -86 <.001
6w -40 -42 .08
9w -53 -56 .43
12w -40 -47 .26
![Page 17: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/17.jpg)
OCT Central Subfield Thickness <250 microns or >50% Decrease in Thickening
Laser (0)N=19
Bev 2.5 (0,6)N=24
3w 11% 38%
6w 17% 22%
9w 19% 22%
12w 21% 33%
![Page 18: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/18.jpg)
Visual Acuity Letter Score Median Change from Baseline
Laser (0)N=19
Bev 2.5 (0,6)N=24
P value
3w -2 +6 .003
6w +1 +6 .03
9w +3 +8 .02
12w -1 +7 .003
![Page 19: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/19.jpg)
Visual Acuity Letter ScoreIncrease > 10 from Baseline
Laser (0)N=19
Bev 2.5 (0,6)N=24
3w 6% 17%
6w 11% 29%
9w 18% 39%
12w 16% 25%
![Page 20: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/20.jpg)
3. Does 2.5 mg bevacizumab produce a greater short-term
reduction in DME than 1.25 mg?Compare Bevacizumab 1.25
mg (0,6) vs. Bevacizumab 2.5 mg (0,6) at 3, 6, 9, and 12 weeks
![Page 21: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/21.jpg)
OCT Central Subfield ThicknessMedian Change (microns) from Baseline
Bev 1.25 (0,6)N=22
Bev 2.5 (0,6)N=24
P value
3w -35 -86 .66
6w -35 -42 .49
9w -74 -56 .45
12w -56 -47 .90
![Page 22: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/22.jpg)
OCT Central Subfield Thickness <250 microns or >50% Decrease in Thickening
Bev 1.25 (0,6)N=22
Bev 2.5 (0,6)N=24
3w 37% 38%
6w 30% 22%
9w 38% 22%
12w 33% 33%
![Page 23: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/23.jpg)
Bev 1.25 (0,6)N=22
Bev 2.5 (0,6)N=24
P value
3w +5 +6 .42
6w +5 +6 .67
9w +7 +8 .48
12w +5 +7 .82
Visual Acuity Letter Score Median Change from Baseline
![Page 24: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/24.jpg)
Bev 1.25 (0,6)N=22
Bev 2.5 (0,6)N=24
3w 19% 17%
6w 32% 29%
9w 29% 39%
12w 33% 25%
Visual Acuity Letter Score Increase> 10 from Baseline
![Page 25: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/25.jpg)
4. What is the duration of effect of the initial injection?
Among eyes with a decrease in CSF thickness of >11% (the reliability limit for real change) from baseline to 3 weeks, evaluate change from 3 weeks to 6 weeks
![Page 26: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/26.jpg)
Duration of Initial Injection Pooling 1.25 mg Groups [Bev 1.25 (0,6) and Bev 1.25 (0)]
OCT CSF % Change 0w to 3w
>11% decrease
(N=14)
Within +11% (N=22)
>11% increase
(N=2)
% Change 3w to 6w>11% decrease 1 2 1
Within +11% 11 16 1
>11% increase 2 4 0
![Page 27: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/27.jpg)
Duration of Initial Injection Bevacizumab 2.5 mg (0,6) Group
OCT CSF % Change 0w to 3w
>11% decrease
(N=13)
Within +11% (N=10)
>11% increase
(N=0)
% Change 3w to 6w>11% decrease 0 0 0
Within +11% 9 9 0
>11% increase 4 1 0
![Page 28: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/28.jpg)
5. What is the duration of effect of the second injection?
Among eyes with a decrease in CSF thickness of at least 11% from 6w to 9w, evaluate change from 9 weeks to 12 weeks
![Page 29: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/29.jpg)
Duration of Second Injection Bevacizumab 1.25 mg (0,6) Group
OCT CSF % Change 6w to 9w
>11% decrease
(N=7)
Within +11% (N=9)
>11% increase
(N=2)
% Change 9w to 12w>11% decrease 0 1 0
Within +11% 4 6 2
>11% increase 3 2 0
![Page 30: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/30.jpg)
Duration of Second Injection Bevacizumab 2.5 mg (0,6) Group
OCT CSF % Change 6w to 9w
>11% decrease
(N=3)
Within +11% (N=17)
>11% increase
(N=2)
% Change 9w to 12w>11% decrease 0 2 1
Within +11% 2 14 1
>11% increase 1 1 0
![Page 31: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/31.jpg)
6. Is there a greater effect with bevacizumab followed by focal laser compared with bevacizumab alone?
Compare (at 12 weeks) bevacizumab 1.25 mg alone vs. bevacizumab 1.25 mg plus laser
![Page 32: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/32.jpg)
Effect of Combining Focal Photocoagulation with Bevacizumab at 12 Weeks
Bev 1.25 (0,6)
Bev 1.25 (0,6)+ Laser (3)
Baseline to 12w
OCT CSF <250 or decrease >50% 33% 25%
VA Letter Score increase > 10 33% 20%
![Page 33: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/33.jpg)
Subgroup Analyses at 3 Weekspooling all bevacizumab groups
Baseline CSF<400 (N=43)
Baseline CSF>=400 (N=41)
P value
MeanCSF microns change
-3 -102 <0.0001
MeanCSF % change in thickening
-2% -26% 0.12
![Page 34: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/34.jpg)
Subgroup Analyses at 3 Weeks
pooling all bevacizumab groups
Baseline VA<65
(N=44)
Baseline VA>=65 (N=43)
P value
MeanVA letters change
+3 +1 0.006
MeanVA % reduction in deficit
+11% +7% 0.40
![Page 35: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/35.jpg)
Subgroup Analyses at 3 Weeks pooling all bevacizumab groups
Chg in CSF thickness (microns)
Chg in VA (letters)
N Median P N Median P
Prior treatmentNoYes
2658
0.16-40 -29
2661
0.04+5 +2
Subretinal fluidDefinite/Questionable No evidence
2163
0.52-35 -29
2166
0.06+6 +1
![Page 36: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/36.jpg)
Subgroup Analyses at 3 Weeks pooling all bevacizumab groups
Change in CSF thickness and change in VA from baseline to 3 weeks did not significantly vary according to:• Age, gender, baseline retinopathy
severity, baseline clinical characterization of DME as focal or diffuse
![Page 37: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/37.jpg)
Outcome during weeks 13-24Among eyes meeting deferral criteria at 12
weeks, deferral criteria were also met at 18 weeks in:• 2 of 4 eyes in Laser (0) Group• 5 of 7 eyes in Bev 1.25 (0,6) Group• 1 of 8 eyes in Bev 2.5 (0,6) Group • 2 of 3 eyes in Bev 1.25 (0) Group • 3 of 5 eyes in Bev 1.25 (0,6) + Laser (3) Group
![Page 38: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/38.jpg)
Ocular Adverse Events
1 eye in the Bev 1.25 (0,6) + Laser (3) Group with endophthalmitis
![Page 39: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/39.jpg)
Cardiovascular Adverse Events
Fatal MI at 16 wks (1.25 inj at 0, 6 wks)
Non-fatal MI at 1 wk (2.5 inj at 0 wks)
CHF at 12 wks (1.25 inj at 0, 7 wks)
![Page 40: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/40.jpg)
Other Systemic Adverse Events Of the 107 subjects treated with bevacizumab
• Death due to cancer (N=1)• Peripheral vascular disease (N=1)• Syncope (N=1)• Elevated BP (N=3)• Worsening renal function (N=3)• Anemia (N=4)
Of the 12 subjects receiving only focal photocoagulation• Peripheral vascular disease (N=2)• Elevated BP (N=1)• Worsening renal function (N=1)• Anemia (N=1)
![Page 41: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/41.jpg)
Comparison of APTC events in Protocols H and B (IVT Study)
B: 11 of 693 (1.6%) subjects reported an APTC event over the first 24 weeks of follow-up
H: 2 of 107 (1.9%) subjects treated with bevacizumab reported an APTC event during the first 24 weeks of follow-up
![Page 42: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/42.jpg)
Conclusions1. There is an apparent effect of 1.25
mg and 2.5 mg of bevacizumab when compared with focal photocoagulation, although the effect appears to be modest
2. It does not appear that 2.5 mg of bevacizumab has an appreciably larger effect on DME than 1.25 mg
![Page 43: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/43.jpg)
Conclusions3. Injection intervals of 4 weeks are
probably more appropriate than intervals of 6 weeks
4. A study arm with combination treatment (bevacizumab plus focal photocoagulation) is feasible from a logistical standpoint
![Page 44: Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health](https://reader034.vdocuments.site/reader034/viewer/2022052515/5a4d1b507f8b9ab0599a76f0/html5/thumbnails/44.jpg)
ConclusionsThe study was designed to evaluate short term effect. No conclusions should be made regarding clinical benefit. A large phase 3 randomized clinical trial is needed for this purpose.